Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 295 Published: September 30, 2022 Report Code: GDGMDHC22317IDB

Schizophrenia Pipeline Drugs Market Report Overview

The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications.

The Schizophrenia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.

Schizophrenia Pipeline Products Market Segmentation by Targets

The key targets in the Schizophrenia pipeline products market are D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Muscarinic Acetylcholine Receptor M4, Muscarinic Acetylcholine Receptor M1, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2, 5-Hydroxytryptamine Receptor 7, Alpha 1B Adrenergic Receptor, cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, and others.

Schizophrenia Pipeline Products Market Analysis by Targets

Schizophrenia Pipeline Products Market Analysis by Targets

For more target insights into the Schizophrenia pipeline products market, download a free report sample

Schizophrenia Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Schizophrenia pipeline products market are 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 1A Agonist, D2 Dopamine Receptor Agonist, Muscarinic Acetylcholine Receptor M4 Agonist, Muscarinic Acetylcholine Receptor M1 Agonist, 5-Hydroxytryptamine Receptor 2 Antagonist, D3 Dopamine Receptor Agonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Alpha 1B Adrenergic Receptor Antagonist, and others.

Schizophrenia Pipeline Products Market Analysis by Mechanisms of Action

Schizophrenia Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Schizophrenia pipeline products market, download a free report sample

Schizophrenia Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Schizophrenia pipeline products market are oral, intramuscular, parenteral, subcutaneous, intravenous, sublingual, nasal, inhalational, and transdermal.

Schizophrenia Pipeline Products Market Analysis by Routes of Administration

Schizophrenia Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Schizophrenia pipeline products market, download a free report sample

Schizophrenia Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Schizophrenia pipeline products market are small molecule, synthetic peptide, monoclonal antibody, cell therapy, and gene-modified cell therapy.

Schizophrenia Pipeline Products Market Analysis by Molecule Types

Schizophrenia Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Schizophrenia pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the Schizophrenia pipeline products market are Omeros Corp, Cerevel Therapeutics Holdings Inc, Luye Pharma Group Ltd, Intra-Cellular Therapies Inc, NeuroSolis Inc, Otsuka Pharmaceutical Co Ltd, Acadia Pharmaceuticals Inc, Autifony Therapeutics Ltd, Bristol-Myers Squibb Co, and MedinCell SA.

Schizophrenia Pipeline Products Market Analysis by Players

Schizophrenia Pipeline Products Market Analysis by Players

To know more about the leading players in the Schizophrenia pipeline products market, download a free report sample

Schizophrenia Pipeline Products Market Report Overview

Key Targets D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Muscarinic Acetylcholine Receptor M4, Muscarinic Acetylcholine Receptor M1, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2, 5-Hydroxytryptamine Receptor 7, Alpha 1B Adrenergic Receptor, cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, and Others
Key Mechanisms of Action 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 1A Agonist, D2 Dopamine Receptor Agonist, Muscarinic Acetylcholine Receptor M4 Agonist, Muscarinic Acetylcholine Receptor M1 Agonist, 5-Hydroxytryptamine Receptor 2 Antagonist, D3 Dopamine Receptor Agonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Alpha 1B Adrenergic Receptor Antagonist, and Others
Key Routes of Administration Oral, Intramuscular, Parenteral, Subcutaneous, Intravenous, Sublingual, Nasal, Inhalational, and Transdermal
Key Molecule Type Small Molecule, Synthetic Peptide, Monoclonal Antibody, Cell Therapy, and Gene-Modified Cell Therapy
Leading Players Omeros Corp, Cerevel Therapeutics Holdings Inc, Luye Pharma Group Ltd, Intra-Cellular Therapies Inc, NeuroSolis Inc, Otsuka Pharmaceutical Co Ltd, Acadia Pharmaceuticals Inc, Autifony Therapeutics Ltd, Bristol-Myers Squibb Co, and MedinCell SA

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

3Z ehf
AbbVie Inc
Acadia Pharmaceuticals Inc
Adamed Pharma SA
Adare Pharma Solutions
Addex Therapeutics Ltd
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Alexza Pharmaceuticals Inc
Ananda Scientific Inc
Anavex Life Sciences Corp
Athira Pharma Inc
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
Avicanna Inc
BCWorld Pharm Co Ltd
Benuvia Therapeutics Inc
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celon Pharma SA
Cerevance Inc
Cerevel Therapeutics Holdings Inc
Curemark LLC
CuroNZ Ltd
Cyclerion Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daya Drug Discoveries Inc
Delpor Inc
Denovo Biopharma LLC
Echo Pharmaceuticals BV
Endosane Pharmaceuticals GmbH
Entheogenix Biosciences Inc
Exscientia Plc
F. Hoffmann-La Roche Ltd
Gabather AB
Gedeon Richter Plc
Genochem SAS
GP Pharm SA
H. Lundbeck AS
Intra-Cellular Therapies Inc
Io Therapeutics Inc
Jaguar Health Inc
Jazz Pharmaceuticals Plc
Jiangsu Enhua Pharmaceutical Group Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Johnson & Johnson
Karuna Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
LB Pharmaceuticals Inc
Lead Discovery Center GmbH
Livzon Pharmaceutical Group Co Ltd
Lohocla Research Corp
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Malachite Innovations Inc
MapLight therapeutics Inc
MedinCell SA
Mental-Heal Ltd
Merck & Co Inc
Midatech Pharma Plc
Mitsubishi Tanabe Pharma Corp
Nanomi BV
Neonc Technologies Inc
Neumora Therapeutics Inc
Neurelis Inc
Neurocrine Biosciences Inc
NeurOp Inc
NeuroSolis Inc
Newron Pharmaceuticals SpA
Nostrum Biodiscovery SL
Novartis AG
Omeros Corp
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
Pasithea Therapeutics Corp
ProMIS Neurosciences Inc
Ra Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Saniona AB
Shanghai Pharmaceutical Group Co Ltd
Shanghai Zhongze Medicine Tech Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Siragen Pharmaceuticals Inc
Sirtsei Pharmaceuticals Inc
SkySea Pharmaceutical Inc
Sosei Group Corp
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
SyneuRx International (Taiwan) Corp
Taho Pharmaceuticals Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
The Greater Cannabis Company Inc
Therapeutic Solutions International Inc
Valentec
Vanda Pharmaceuticals Inc
Verge Genomics
Vivozon Inc
Whan In Pharm Co Ltd
YaoPharma Co Ltd
Yoda Pharmaceuticals Inc
Zhejiang Jingxin Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Schizophrenia – Overview

Schizophrenia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Schizophrenia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Schizophrenia – Companies Involved in Therapeutics Development

Schizophrenia – Drug Profiles

Schizophrenia – Dormant Projects

Schizophrenia – Discontinued Products

Schizophrenia – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Schizophrenia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Schizophrenia – Dormant Projects, 2022

Schizophrenia – Discontinued Products, 2022

Schizophrenia – Discontinued Products, 2022 (Contd..1)

Schizophrenia – Discontinued Products, 2022 (Contd..2)

List of Figures

List of Figures

Number of Products under Development for Schizophrenia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

The key targets in the Schizophrenia pipeline products market are D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Muscarinic Acetylcholine Receptor M4, Muscarinic Acetylcholine Receptor M1, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2, 5-Hydroxytryptamine Receptor 7, Alpha 1B Adrenergic Receptor, cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, and others.

The key mechanisms of action in the Schizophrenia pipeline products market are 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 1A Agonist, D2 Dopamine Receptor Agonist, Muscarinic Acetylcholine Receptor M4 Agonist, Muscarinic Acetylcholine Receptor M1 Agonist, 5-Hydroxytryptamine Receptor 2 Antagonist, D3 Dopamine Receptor Agonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Alpha 1B Adrenergic Receptor Antagonist, and others.

The key routes of administration in the Schizophrenia pipeline products market are oral, intramuscular, parenteral, subcutaneous, intravenous, sublingual, nasal, inhalational, and transdermal.

The key molecule types in the Schizophrenia pipeline products market are small molecule, synthetic peptide, monoclonal antibody, cell therapy, and gene-modified cell therapy.

 

 

 

Some of the leading players in the Schizophrenia pipeline products market are Omeros Corp, Cerevel Therapeutics Holdings Inc, Luye Pharma Group Ltd, Intra-Cellular Therapies Inc, NeuroSolis Inc, Otsuka Pharmaceutical Co Ltd, Acadia Pharmaceuticals Inc, Autifony Therapeutics Ltd, Bristol-Myers Squibb Co, and MedinCell SA.

$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Pharmaceuticals
New
Heart Failure Epidemiology Analysis and Forecast to 2032
$3,995 | September 2023
Pharmaceuticals
New
Genomics in pharma: genetic engineered T-cells
$250 | September 2023